Leap Therapeutics, Inc.2025财年第一财季实现净利润-15.44百万美元，同比减少11.72%

市场透视05-19

5月19日，Leap Therapeutics, Inc.（LPTX.US）公布财报，公告显示公司2025财年第一财季净利润为-15.44百万美元，同比减少11.72%；其中营业收入为0.00美元，每股基本收益为-0.37美元。从资产负债表来看，Leap Therapeutics, Inc.（LPTX.US）总负债14.04百万美元，其中短期债务517000.00美元，资产负债比为2.49，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2536594155?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-19 00:01","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2536594155","market":"us","top_or_hot":-1,"title":"Leap Therapeutics, Inc.2025财年第一财季实现净利润-15.44百万美元，同比减少11.72%","media":"市场透视","content":"<div>\n<p>5月19日，Leap Therapeutics, Inc.（LPTX.US）公布财报，公告显示公司2025财年第一财季净利润为-15.44百万美元，同比减少11.72%；其中营业收入为0.00美元，每股基本收益为-0.37美元。从资产负债表来看，Leap Therapeutics, Inc.（LPTX.US）总负债14.04百万美元，其中短期债务517000.00美元，资产负债比为2.49，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000530a6e3a85a&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Leap Therapeutics, Inc.2025财年第一财季实现净利润-15.44百万美元，同比减少11.72%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLeap Therapeutics, Inc.2025财年第一财季实现净利润-15.44百万美元，同比减少11.72%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-19 00:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000530a6e3a85a&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5月19日，Leap Therapeutics, Inc.（LPTX.US）公布财报，公告显示公司2025财年第一财季净利润为-15.44百万美元，同比减少11.72%；其中营业收入为0.00美元，每股基本收益为-0.37美元。从资产负债表来看，Leap Therapeutics, Inc.（LPTX.US）总负债14.04百万美元，其中短期债务517000.00美元，资产负债比为2.49，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000530a6e3a85a&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000530a6e3a85a&s=b","article_id":"2536594155","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000530a6e3a85a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2536594155","pubTimestamp":1747584093,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"5月19日，Leap Therapeutics, Inc.公布财报，公告显示公司2025财年第一财季净利润为-15.44百万美元，同比减少11.72%；其中营业收入为0.00美元，每股基本收益为-0.37美元。从资产负债表来看，Leap Therapeutics, Inc.总负债14.04百万美元，其中短期债务517000.00美元，资产负债比为2.49，流动比率为2.42。机构评级：截至2025年5月19日，当前有1家机构对Leap Therapeutics, Inc.目标价做出预测，其中目标均价为5.50美元，其中最低目标价为5.50美元，最高目标价为5.50美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"LENZ":"Therapeutics"},"translate_title":"Leap Therapeutics, Inc. achieved net profit of-US $15.44 million in the first fiscal quarter of fiscal year 2025, a year-on-year decrease of 11.72%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LPTX":0.9,"LENZ":1},"content_text":"5月19日，Leap Therapeutics, Inc.（LPTX.US）公布财报，公告显示公司2025财年第一财季净利润为-15.44百万美元，同比减少11.72%；其中营业收入为0.00美元，每股基本收益为-0.37美元。从资产负债表来看，Leap Therapeutics, Inc.（LPTX.US）总负债14.04百万美元，其中短期债务517000.00美元，资产负债比为2.49，流动比率为2.42。机构评级：截至2025年5月19日，当前有1家机构对Leap Therapeutics, Inc.目标价做出预测，其中目标均价为5.50美元，其中最低目标价为5.50美元，最高目标价为5.50美元。公司简介：Leap Therapeutics Inc 是一家生物制药公司，开发新型生物标志物靶向抗体疗法，旨在通过抑制基本的肿瘤促进途径、靶向癌症特异性细胞表面分子和利用免疫系统攻击癌细胞来治疗癌症患者。该公司的关键临床阶段候选药物是 sirexatamab （DKN-01），其靶向 Dickkopf 相关蛋白 1 （DKK1），目前正在结直肠癌患者中进行临床试验。此外，它还有一个临床前计划，以开发一种名为 FL-501 的专有单克隆抗体，该抗体通过抑制 GDF-15 蛋白起作用。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2536594155","isCrawlerRequest":true}